Brief: Vivos Therapeutics Files For Non-Timely 10-Q With US SEC
14/11/2025 21:07
Nov 14 (Reuters) - Vivos Therapeutics Inc VVOS.O: VIVOS THERAPEUTICS INC: FILES FOR NON-TIMELY 10-Q WITH U.S. SEC VIVOS THERAPEUTICS INC -ANTICIPATES THAT ITS REVENUE INCREASED BY OVER 50% FOR THREE MONTHS ENDED SEPTEMBER 30 VIVOS THERAPEUTICS INC -ANTICIPATES INCREASE IN ITS NET LOSS FOR THREE MONTHS ENDED SEPTEMBER 30, 2025 VERSUS THREE MONTHS ENDED SEPT 30, 2024 Source text: [ID:n0001493152-25-023404] Further company coverage: VVOS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vivos Therapeutics
See all newsBrief: Vivos Therapeutics Closes Acquisition Of Stake In Sod Sciences And 50% Interest In Pseudohypoxia Test, Opening A Potential Path To Access More Than 325,000 New Patients Through The Aha Channel
Brief: Vivos Therapeutics - Audit Reports For Fy2025 And Fy2024 Include Substantial Doubt About Going Concern
Brief: Vivos Therapeutics And South Palm Cardiovascular Associates Sign Definitive Agreements To Launch Regional Sleep Testing And Treatment Center
Vivos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Vivos Therapeutics Q2 revenue rises 35% on service growth